Quest PharmaTech Announces Dosing Of First Patient In Its Prostate Cancer Clinical Trial

14-May-2010 - Quest PharmaTech Inc. announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 ...

Quest PharmaTech Signs Agreement to sell Bionex Technology

13-May-2008 - Quest PharmaTech Inc. announced that it has signed a Technology Transfer Agreement with Peking Marvel Cleansing Supplies Co., Ltd., a China-based company, to sell its interest in the Bionex Technology. Peking Marvel is anticipated to be acquired by a TSX NEX listed company called Toba Industries ...

Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer

30-Jan-2008 - Quest PharmaTech Inc. announced that it has signed a collaborative research agreement with the BC Cancer Agency (the "BCCA") to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the Company's lead oncology product, SL052, with various ...

Quest PharmaTech and Paramount BioSciences Sign Exclusive Multinational License Agreement for SonoLight Technology

16-May-2007 - Quest PharmaTech Inc. announced that Paramount BioSciences, LLC, has acquired multinational rights to Quest's proprietary SonoLight technology for dermatology applications. The deal gives Paramount BioSciences access to a library of Hypocrellin B-derived photosensitizers which are activated by ...

Quest PharmaTech announces sale of non-core assets

Quest disengages completely from China

11-Aug-2006 - Quest PharmaTech Inc. has signed an agreement with Shanghai Gaojing Capital Management Co. Ltd., to sell its manufacturing plant in China (Shanghai Hua Gao Pellet Core Pharmaceutical Ltd. or SHGP) for gross proceeds of 1,250,000 RMB (about $175,000). As part of this transaction, the Gaojing ...